INS and male reproductive organ cancer: Contraindicated in ketoacidosis; back pain; cystitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulfonylurea); increased risk of infection; prostatitis; skin reactions; urinary and vulvovaginal disorders.The treatment should be discontinued when pregnancy is detected, not recommended for the 2nd and 3rd trimester of pregnancy.